SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    William T. Senapedis, Erkan Baloglu, Yosef Landesman, Clinical translation of nuclear export inhibitors in cancer, Seminars in Cancer Biology, 2014, 27, 74

    CrossRef

  2. 2
    J J Ko, T K Choueiri, B I Rini, J-L Lee, N Kroeger, S Srinivas, L C Harshman, J J Knox, G A Bjarnason, M J MacKenzie, L Wood, U N Vaishampayan, N Agarwal, S K Pal, M-H Tan, S Y Rha, T Yuasa, F Donskov, A Bamias, D Y C Heng, First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC, British Journal of Cancer, 2014, 110, 8, 1917

    CrossRef

  3. 3
    Hidenori Kawashima, Aiko Obayashi, Marie Kawamura, Sakae Masaki, Satoshi Tamada, Taro Iguchi, Junji Uchida, Katsuyuki Kuratsukuri, Tomoaki Tanaka, Tatsuya Nakatani, Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides, BJU International, 2014, 113, 2
  4. 4
    Kaushal Parikh, Shundong Cang, Arunabh Sekhri, Delong Liu, Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents, Journal of Hematology & Oncology, 2014, 7, 1, 78

    CrossRef

  5. 5
    Simon L. Conti, I-Chun Thomas, Judith C. Hagedorn, Benjamin I. Chung, Glenn M. Chertow, Todd H. Wagner, James D. Brooks, Sandy Srinivas, John T. Leppert, Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era, International Journal of Cancer, 2014, 134, 9
  6. 6
    Srikala S. Sridhar, Mary J. Mackenzie, Sebastien J. Hotte, Som D. Mukherjee, Ian F. Tannock, Nevin Murray, Christian Kollmannsberger, Masoom A. Haider, Eric X. Chen, Robert Halford, Lisa Wang, S. Percy Ivy, Malcolm J. Moore, A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium, Investigational New Drugs, 2013, 31, 4, 1008

    CrossRef

  7. 7
    Hiromi I. Wettersten, Robert H. Weiss, Applications of Metabolomics for Kidney Disease Research, Organogenesis, 2013, 9, 1, 11

    CrossRef

  8. 8
    Hiromi Inoue, Michael Kauffman, Sharon Shacham, Yosef Landesman, Joy Yang, Christopher P. Evans, Robert H. Weiss, CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth, The Journal of Urology, 2013, 189, 6, 2317

    CrossRef

  9. 9
    Sherri M. Donat, Mireya Diaz, Jay Todd Bishoff, Jonathan A. Coleman, Philipp Dahm, Ithaar H. Derweesh, S. Duke Herrell, Susan Hilton, Eric Jonasch, Daniel W. Lin, Victor E. Reuter, Sam S. Chang, Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline, The Journal of Urology, 2013, 190, 2, 407

    CrossRef

  10. 10
    Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły, Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications, Cancer Letters, 2013, 341, 2, 111

    CrossRef

  11. 11
    George Philips, Michael B. Atkins, Is Interleukin 2 the Best Initial Therapy for Many Patients With Metastatic Renal Cell Carcinoma?, The Cancer Journal, 2013, 19, 3, 197

    CrossRef

  12. 12
    Hiromi I. Wettersten, Robert H. Weiss, Potential biofluid markers and treatment targets for renal cell carcinoma, Nature Reviews Urology, 2013, 10, 6, 336

    CrossRef

  13. 13
    Frédéric D. Birkhäuser, Allan J. Pantuck, Edward N. Rampersaud, Xiaoyan Wang, Nils Kroeger, Frédéric Pouliot, Nazy Zomorodian, Joseph Riss, Gang Li, Fairooz F. Kabbinavar, Arie S. Belldegrun, Salvage-Targeted Kidney Cancer Therapy in Patients Progressing on High-Dose Interleukin-2 Immunotherapy, The Cancer Journal, 2013, 19, 3, 189

    CrossRef

  14. 14
    Mu-Yan Cai, Rong-Zhen Luo, Yong-Hong Li, Pei Dong, Zhi-Ling Zhang, Fang-Jian Zhou, Jie-Wei Chen, Jing-Ping Yun, Chris Zhi-Yi Zhang, Yun Cao, High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma, Biochemical and Biophysical Research Communications, 2012, 426, 4, 636

    CrossRef

  15. 15
    Bernard Escudier, Susanne Osanto, Börje Ljungberg, Camillo Porta, John Wagstaff, Peter Mulders, Martin Gore, Axel Bex, Joaquim Bellmunt, Sergio Bracarda, Alex Franklin, Per Hartvig Honoré, Alain Ravaud, Jeanne van Steijn, Zeba Aziz, Hideyuki Akaza, Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies, Cancer Treatment Reviews, 2012, 38, 2, 127

    CrossRef

  16. 16
    Laurie J. Eisengart, Gary R. MacVicar, Ximing J. Yang, Predictors of Response to Targeted Therapy in Renal Cell Carcinoma, Archives of Pathology & Laboratory Medicine, 2012, 136, 5, 490

    CrossRef

  17. 17
    Nils Kroeger, Tobias Klatte, Frédéric D. Birkhäuser, Edward N. Rampersaud, David B. Seligson, Nazy Zomorodian, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J. Pantuck, Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival, Cancer, 2012, 118, 7
  18. 18
    Raj Kurpad, William Kim, W. Kim Rathmell, Paul Godley, Young Whang, Julia Fielding, LuAnn Smith, Ava Pettiford, Heather Schultz, Matthew Nielsen, Eric M. Wallen, Raj S. Pruthi, A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions?, Urologic Oncology: Seminars and Original Investigations, 2011, 29, 4, 378

    CrossRef

  19. 19
    H. Akaza, T. Tsukamoto, T. Fujioka, Y. Tomita, T. Kitamura, S. Ozono, T. Miki, S. Naito, H. Zembutsu, Y. Nakamura, Combined Immunotherapy with Low-dose IL-2 Plus IFN-  for Metastatic Renal Cell Carcinoma: Survival Benefit for Selected Patients with Lung Metastasis and Serum Sodium Level, Japanese Journal of Clinical Oncology, 2011, 41, 8, 1023

    CrossRef

  20. 20
    Emiliano Calvo Aller, Pablo Maroto, Noémi Kreif, José Luis González Larriba, Marta López-Brea, Daniel Castellano, Belén Martí, Silvia Díaz Cerezo, Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain, Clinical and Translational Oncology, 2011, 13, 12, 869

    CrossRef

  21. 21
    A Leary, JM Larkin, Lisa M Pickering, Cytokine therapy for renal cell cancer: the evolving role of immunomodulation, Therapy, 2011, 8, 4, 347

    CrossRef

  22. 22
    A. Goh, A. Vathsala, Native Renal Cysts and Dialysis Duration Are Risk Factors for Renal Cell Carcinoma in Renal Transplant Recipients, American Journal of Transplantation, 2011, 11, 1
  23. 23
    Tobias Klatte, Jonathan W. Said, David B. Seligson, P. Nagesh Rao, Michela de Martino, Brian Shuch, Nazy Zomorodian, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J. Pantuck, Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features, The Journal of Urology, 2011, 185, 1, 30

    CrossRef

  24. 24
    Alexandra Leary, James MG Larkin, Lisa M Pickering, Targeted Therapies for Renal Cell Carcinoma, 2011,

    CrossRef

  25. 25
    Tobias Klatte, Mesut Remzi, Richard E. Zigeuner, Sebastian Mannweiler, Jonathan W. Said, Fairooz F. Kabbinavar, Andrea Haitel, Matthias Waldert, Michela de Martino, Michael Marberger, Arie S. Belldegrun, Allan J. Pantuck, Development and External Validation of a Nomogram Predicting Disease Specific Survival After Nephrectomy for Papillary Renal Cell Carcinoma, The Journal of Urology, 2010, 184, 1, 53

    CrossRef

  26. You have free access to this content26
    Takeshi Kishida, Masahiro Yao, Hirotsugu Uemura, Carsten Ohlmann, Yoshihiko Tomita, Ronald M Bukowski, Sei Naito, Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy, International Journal of Urology, 2010, 17, 3
  27. 27
    Roberto Iacovelli, Cristina Raimondi, Antonella Palazzo, Enrico Cortesi, Giuseppe Procopio, Neoadjuvant targeted therapy in renal cell carcinoma, Nature Reviews Urology, 2010, 7, 7

    CrossRef

  28. 28
    H. Akaza, K. Kawai, T. Tsukamoto, T. Fujioka, Y. Tomita, T. Kitamura, S. Ozono, T. Miki, S. Naito, H. Zembutsu, Y. Nakamura, Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon-  for Renal Cell Carcinoma Patients with Lung Metastasis, Japanese Journal of Clinical Oncology, 2010, 40, 7, 684

    CrossRef

  29. 29
    Alexander Kutikov, Robert G. Uzzo, Aaron Caraway, Carl T. Reese, Brian L. Egleston, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Yu-Ning Wong, Jay D. Raman, Stephen A. Boorjian, Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy, BJU International, 2010, 106, 2